A BLADDER cancer clinical trial funded by Yorkshire Cancer Research is now recruiting patients.
The ‘BRAVO’ study, led by Professor James Catto at the University of Sheffield, will compare two types of treatment for aggressive bladder cancer.
Patients with tumours that are detected before the cancer has invaded muscle can be treated with immediate bladder removal, called a cystectomy, or a bladder-preserving therapy known as BCG.
Bladder-preserving therapy is the standard approach and involves a three-year treatment plan, but only a third of patients complete the course due to side effects and a quarter go on to need a cystectomy anyway.
The issue has been raised by the National Institute for Health and Care Excellence (NICE) as one of the top five bladder cancer research priorities.
The trial will involve the recruitment of 60 patients with bladder cancer from across Yorkshire and Humber. Half the patients will receive BCG therapy and half will undergo a cystectomy. If successful, the trial will be expanded nationally.
Incidence and mortality rates of bladder cancer in Yorkshire are higher than the national average. Incidence rates are particularly high in North Kirklees, Hull and East Riding CCGs, while mortality rates are highest in North Kirklees, Wakefield and South Tees CCGs.
Professor James Catto, Professor of Urology at the University of Sheffield, said: “Bladder cancer is a huge problem in Yorkshire. We are therefore very excited to have opened this vital clinical trial. The results of this study will be essential in helping us understand whether we will be able to undertake a larger, national trial.”
Patients from across Yorkshire will be eligible for the trial if they have been recently diagnosed with aggressive, but not invasive, bladder cancer. For more information, please contact Dr Maureen Twiddy, Research Fellow at the University of Leeds, by emailing email@example.com.
Nikki Brady, Senior PR Officer, Yorkshire Cancer Research. Tel: 01423 877228. Email: firstname.lastname@example.org
Notes to Editors
- Harrogate-based Yorkshire Cancer Research was founded in 1925 and is the largest independent regional cancer charity in England (Registered Charity 516898). We are not part of a national charity.
- We are committed to reducing the devastating impact of cancer on the lives of people living in Yorkshire.
- Our mission is to work in partnership, fund research and support initiatives that will help people in Yorkshire avoid, survive and cope with cancer.
- Current statistics show that 575 people are diagnosed with cancer in Yorkshire every week. Incidence and mortality rates are higher than the England average due to social deprivation, post-industrialisation and lifestyle choices but also availability of healthcare services and difficulties accessing early diagnostics, clinical trials and the latest treatments.
- We aim to:
- Be the leading authority on cancer in Yorkshire, understanding the problems and priorities in the region and sharing knowledge with partners.
- Raise awareness of cancer and how to prevent it by working in local communities, schools and colleges, sports clubs and with other health-related organisations.
- Promote screening programmes and fund research that can improve the diagnosis of cancer so we can detect and treat it at the earliest opportunity.
- Invest in innovative research projects at every stage of a cancer patient's journey.
- Campaign for fair and equal access to the very best healthcare services and a greater share of the money spent nationally on research.
- For further information, please visit www.yorkshirecancerresearch.org.uk or follow us on Facebook or Twitter.